Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02393794 · ClinicalTrials.gov registry record · Phase 1
Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
A Phase 1 study of Breast Cancer and Triple Negative Breast Cancer, sponsored by Priyanka Sharma.
- Active
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
- 7
- Study locations
NCT02393794: Active Phase 1 study of Breast Cancer and Triple Negative Breast Cancer, sponsored by Priyanka Sharma.
NCT02393794 is a Phase 1 study of Breast Cancer and Triple Negative Breast Cancer that is active but no longer recruiting, run by Priyanka Sharma. The registered enrollment target is 51 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02393794, a Phase 1 study of Breast Cancer and Triple Negative Breast Cancer, is active but no longer recruiting, sponsored by Priyanka Sharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
- 7
- Study locations
Study Summary
Study combination use of cisplatin plus romidepsin and nivolumab in metastatic triple negative breast cancer (TNBC) or BRCA mutation-associated locally recurrent or metastatic breast cancer
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Nivolumab
- DRUG Romidepsin
Study Locations (7)
Kansas
- University of Kansas Cancer Center - Clinical Research Center - Fairway
- University of Kansas Cancer Center - West - Kansas City
- University of Kansas Cancer Center - Overland Park - Overland Park
- University of Kansas Cancer Center - Westwood - Westwood
Missouri
- University of Kansas Cancer Center - South - Kansas City
- University of Kansas Cancer Center - North - Kansas City
- University of Kansas Cancer Center - Lee's Summit - Lee's Summit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2015-07-17 |
| Est. Completion | 2026-07 |
| Phase | Phase 1 |
What the registry record for NCT02393794 still lists
NCT02393794 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cisplatin is the first listed.
NCT02393794 lists 7 locations in 2 states (Kansas, Missouri).
Frequently Asked Questions
What is clinical trial NCT02393794 about?
NCT02393794 is a clinical study titled "Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)". Study combination use of cisplatin plus romidepsin and nivolumab in metastatic triple negative breast cancer (TNBC) or BRCA mutation-associated locally recurrent or metastatic breast cancer
What is the current status of trial NCT02393794?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2015-07-17. Estimated completion is 2026-07.
What conditions does trial NCT02393794 study?
This clinical trial studies the following conditions: Breast Cancer, Triple Negative Breast Cancer.
What interventions are being tested in trial NCT02393794?
The interventions under investigation include: Cisplatin (DRUG), Nivolumab (DRUG), Romidepsin (DRUG).
Who is sponsoring clinical trial NCT02393794?
This trial is sponsored by Priyanka Sharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02393794 being conducted?
This trial has 7 study locations across Kansas, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02393794's enrollment target sits among peer trials
51 782nd of 1224 higher than 437 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI